Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Clinical trial NCT07296705 · RECRUITING
Trial details
- NCT number
- NCT07296705
- Sponsor
- Fujian Medical University Union Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-25
- Primary completion
- 2027-12-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.